Frontiers in Oncology (Mar 2023)

Self-supervised contrastive learning using CT images for PD-1/PD-L1 expression prediction in hepatocellular carcinoma

  • Tianshu Xie,
  • Yi Wei,
  • Lifeng Xu,
  • Qian Li,
  • Feng Che,
  • Qing Xu,
  • Xuan Cheng,
  • Minghui Liu,
  • Meiyi Yang,
  • Xiaomin Wang,
  • Feng Zhang,
  • Bin Song,
  • Bin Song,
  • Ming Liu,
  • Ming Liu

DOI
https://doi.org/10.3389/fonc.2023.1103521
Journal volume & issue
Vol. 13

Abstract

Read online

Background and purposeProgrammed cell death protein-1 (PD-1) and programmed cell death-ligand-1 (PD-L1) expression status, determined by immunohistochemistry (IHC) of specimens, can discriminate patients with hepatocellular carcinoma (HCC) who can derive the most benefits from immune checkpoint inhibitor (ICI) therapy. A non-invasive method of measuring PD-1/PD-L1 expression is urgently needed for clinical decision support.Materials and methodsWe included a cohort of 87 patients with HCC from the West China Hospital and analyzed 3094 CT images to develop and validate our prediction model. We propose a novel deep learning-based predictor, Contrastive Learning Network (CLNet), which is trained with self-supervised contrastive learning to better extract deep representations of computed tomography (CT) images for the prediction of PD-1 and PD-L1 expression.ResultsOur results show that CLNet exhibited an AUC of 86.56% for PD-1 expression and an AUC of 83.93% for PD-L1 expression, outperforming other deep learning and machine learning models.ConclusionsWe demonstrated that a non-invasive deep learning-based model trained with self-supervised contrastive learning could accurately predict the PD-1 and PD-L1 expression status, and might assist the precision treatment of patients withHCC, in particular the use of immune checkpoint inhibitors.

Keywords